Clinical trials: Colorectal Cancer Metastatic
Colorectal Neoplasms, Peritoneal Neoplasms
PIPAC for Peritoneal Metastases of Colorectal Cancer
This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol…
- Conditions
- Colorectal Neoplasms, Peritoneal Neoplasms, Appendiceal Neoplasms, Peritoneal Carcinomatosis
- Trial name
- CRC-PIPAC (NCT03246321)
- Testing
- repetitive ePIPAC-OX
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Koen Rovers
Neoplasms
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that: has spread to other parts of the…
- Trial name
- NCT04607421
- Testing
- Encorafenib, Cetuximab, Oxaliplatin
- Where
- 274 sites in United States, Argentina and 27 more
- Volunteers
- 841 people
- Sponsor
- Pfizer
GI Cancer
Improving Diagnosis and Treatment for Patients With Rectal Cancer
The cancer stage information from scans guides pre-operative treatment and the type of surgery offered. The investigators are studying whether a new Magnetic Resonance Imaging (MRI) staging method can improve the accuracy of…
- Trial name
- MERCURY 3 (NCT07054047)
- Testing
- mrTDV
- Where
- 3 sites in United Kingdom
- Volunteers
- 438 people
- Sponsor
- Imperial College London
Colorectal Cancer, Liver Metastases
Prognostic Factors and Oncological Outcomes in Laparoscopic Liver Resection for CRLM
Laparoscopic liver resection (LLR) has gained acceptance as an effective treatment for colorectal liver metastases (CRLM) in selected patients, providing similar oncologic outcomes compared to open liver resection (OLR).
- Conditions
- Colorectal Cancer, Liver Metastases, Surgery
- Trial name
- NCT05036265
- Volunteers
- 200 people
- Sponsor
- General Hospital Groeninge
Microsatellite Instability, Lynch Syndrome
MSI in Circulatory DNA of Endometrial Cancer
This study aims to analyze the microsatellite instability (MSI) in the circulatory tumor DNA and in the tumor tissue in the patients diagnosed with uterine endometrial cancer.
- Conditions
- Microsatellite Instability, Lynch Syndrome, Endometrial Cancer, Circulating Tumor Cell
- Trial name
- NCT03744962
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lei Li
Colorectal Cancer, Colon Cancer
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) and Aldesleukin (interleukin-2, IL-2) immunotherapy in patients with…
- Conditions
- Colorectal Cancer, Colon Cancer, Rectum Cancer
- Trial name
- BAH248 (NCT06530303)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Colorectal Cancer, Refractory Colorectal Cancer
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT06202417
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 520 people
- Sponsor
- Fudan University
Neoplasms, Therapy-Associated
The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer
Through clinical observation and data statistics, conclude the clinical outcome of target therapy in metastasis colorectal cancer and explore some biomarkers that relate to target therapy.
- Trial name
- NCT02523495
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Huazhong University of Science and Technology
Colorectal Neoplasms
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
Correlation and Heterogeneity of the Immune Microenvironment and Histopathological Growth Patterns in Resectable Colorectal Cancer Liver Metastases
- Trial name
- CRLM (NCT07564908)
- Testing
- Formalin-fixed, paraffin-embedded (FFPE) sections of colorectal cancer liver metastases were stained with hematoxylin and eosin (H&E) and Multiplex immunohistochemistry (mIHC) staining.
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Meng Qiu
Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma
To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
Pancreatic, ovarian and colorectal cancers are difficult to treat using chemotherapy and immune therapies.Currently most patients are offered treatment with a standard chemotherapy drug depending on their cancer type.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Ovarian Serous Adenocarcinoma, Colorectal Cancer Metastatic
- Trial name
- CAM-PLEX (NCT02179970)
- Testing
- Plerixafor
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- CCTU- Cancer Theme
Colorectal Cancer
Genes That Affect Disease Outcome in Patients With Metastatic Colorectal Cancer
RATIONALE: Studying samples of blood and tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and help doctors understand how patients respond to treatment.
- Trial name
- NCT00467129
- Testing
- microarray analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 800 people
- Sponsor
- University of Sheffield
Metastatic Colorectal Cancer
Lonsurf® (Trifluridine/Tipiracil) Plus Chemotherapy in Metastatic Colorectal Cancer Prospective Study in Taiwan
Primary Endpoint : To evaluate the Disease control rate (DCR) Secondary Endpoints: To evaluate the Progression-free survival (PFS), Overall survival(OS) and Safety profile
- Trial name
- NCT06495463
- Testing
- Trifluridine/tipiracil
- Where
- Taiwan
- Volunteers
- 97 people
- Sponsor
- Chang Gung Memorial Hospital
Metastatic Colorectal Cancer
Metformin and 5-fluorouracil for Refractory Colorectal Cancer.
This is a phase II trial to evaluate efficacy and safety of Metformin and Fluorouracil in patients with metastatic colorectal cancer (CRC) who have progressed after Oxaliplatin and Irinotecan based chemotherapy.
- Trial name
- NCT01941953
- Testing
- Metformin and Fluorouracil
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Colorectal Cancer, Metastasis
Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer
The standard treatment of metastatic colorectal cancer is based on systemic chemotherapy. Several effective drugs are currently available and can be administered either sequentially or in combination.
- Trial name
- NCT00126256
- Testing
- 5-fluorouracil, leucovorin, irinotecan
- Where
- France
- Volunteers
- 570 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that…
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT00569127
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate
- Where
- 493 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Sarcoma
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of EBNK-001 (allogeneic NK cells) given after lymphodepleting cyclophosphamide/fludarabine (CY/FLU) and supported with low-dose IL-15…
- Conditions
- Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- EBNK-ST-001 (NCT07410676)
- Testing
- EBNK-001 + IL-15 + Pembrolizumab
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Essen Biotech
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
Colorectal Liver Metastases, Quality of Life
Quality of Life and Liver Metastases
An increasing aggressiveness in the surgical approach of colorectal liver metastases is observed. This seems only justified when, besides prolongation of survival, also the health status of patients is considered.
- Trial name
- NCT00184834
- Testing
- quality of life
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003001
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Stony Brook University